The FDA has begun soliciting feedback to inform the next version of the Prescription Drug User Fee Act. User fees remain ...

A new Massachusetts law may be the most far-reaching U.S. state legislation aimed at curtailing the influence of private equity in health care. It could serve as a model for other jurisdictions.

The Trump administration’s proposed 15% cap on indirect-cost rates for National Institutes of Health grants risks upending the paradigm that underpins American leadership in medical research.

A 56-year-old woman experiencing homelessness was evaluated at this hospital because of sore throat and a pruritic rash on her face, chest, abdomen, and legs. A diagnosis was made. What is the ...

To prevent the spread of inaccurate information, academic and health care institutions will need to equip scientists and clinicians to engage effectively on nontraditional media platforms.

This Double Take video explores the link between certain strains of human papillomavirus and cancer and reviews the evidence ...

During the Covid-19 pandemic, patients have asked courts to compel hospitals to administer unproven therapies, including ivermectin. These lawsuits have called into question the judiciary’s role ...

NEJM uses highly rigorous editorial, peer, and statistical review processes to evaluate manuscripts for scientific accuracy, novelty, and importance.

In 15 patients with primary aldosteronism, baxdrostat (a second-generation, nonimidazole aldosterone synthase inhibitor) resolved or reduced the severity of hypertension, excessive aldosterone ...

A woman with aggressive refractory systemic lupus erythematosus was treated with a short course of the bispecific antibody teclistamab (anti–B-cell maturation antigen and anti-CD3) and had a ...

Whether proton-pump inhibitors are beneficial or harmful for stress ulcer prophylaxis in critically ill patients undergoing invasive ventilation is unclear. In this international, randomized trial, ...

The FDA often exercises flexibility in deciding whether to approve highly promising drugs for patients in desperate need of treatment options. But it doesn’t consider a drug’s likely financial ...